ChartMill · Sep 25, 2026
Curious about the stocks that are showing activity after the closing bell on Friday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
GO
NASDAQ · GOSS
Gossamer Bio, Inc.
Healthcare · Biotechnology
$11.85
Up+$0.27 (+2.33%)
Updated Oct 1, 2026, 5:32 AM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 824.25M
- P/E ratio
- -5.95
- Dividend yield
- 0.00%
- 52-week range
- $0.11 – $14.75
- Volume
- 382.02K
- Avg. volume
- 3.24M
Price performance · GOSS
GOSS price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Sep 30, 2026
GOSS closed at $11.85 after 20 trading sessions, up 6761.61% for the selected period.
- Last close
- $11.85
- Period change
- +6761.61%
- Period low
- $0.17
- Period high
- $14.39
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 30, 2026 | $11.53 | $12.46 | $11.16 | $11.85 | 382.02K |
| Sep 29, 2026 | $11.68 | $11.845 | $11.21 | $11.58 | 384.01K |
| Sep 28, 2026 | $10.46 | $11.85 | $10.33 | $11.52 | 516.47K |
| Sep 25, 2026 | $10.93 | $11.01 | $10.2225 | $10.94 | 426.59K |
| Sep 24, 2026 | $10.76 | $11.679 | $10.75 | $10.93 | 236.25K |
| Sep 23, 2026 | $11.69 | $11.97 | $10.03 | $10.99 | 455.82K |
| Sep 22, 2026 | $11.48 | $12.3099 | $11.35 | $11.69 | 195.83K |
| Sep 21, 2026 | $11.60 | $11.94 | $10.91 | $11.28 | 258.91K |
| Sep 18, 2026 | $12.00 | $12.49 | $10.67 | $10.73 | 530.22K |
| Sep 17, 2026 | $11.78 | $12.45 | $11.282 | $11.94 | 267.68K |
| Sep 16, 2026 | $10.77 | $11.24 | $9.961 | $10.96 | 272.29K |
| Sep 15, 2026 | $10.61 | $10.97 | $10.12 | $10.38 | 220.5K |
| Sep 14, 2026 | $10.95 | $11.0782 | $10.07 | $10.70 | 325.91K |
| Sep 11, 2026 | $12.48 | $12.52 | $10.47 | $10.73 | 474.15K |
| Sep 10, 2026 | $12.216 | $12.536 | $11.216 | $11.392 | 165.33K |
| Sep 9, 2026 | $12.00 | $13.784 | $11.992 | $12.776 | 296.18K |
| Sep 8, 2026 | $13.72 | $14.752 | $13.464 | $14.392 | 86.49K |
| Sep 4, 2026 | $0.1715 | $0.1807 | $0.168 | $0.1753 | 8.09M |
| Sep 3, 2026 | $0.173 | $0.176 | $0.1635 | $0.1756 | 5.73M |
| Sep 2, 2026 | $0.1656 | $0.1732 | $0.1614 | $0.1727 | 5.76M |
Latest GOSS news
The latest Smart Investors Daily articles mentioning GOSS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GOSS research
Overview
Company profile and research snapshot.
Company profile
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $9.00
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | Piper Sandler | Overweight | — |
| Jul 28, 2026 | Leerink Partners | Outperform | — |
| Jul 27, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 25, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 25, 2026
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Onconetix (NASDAQ:ONCO) stock increased by 10.3% to $1.14 during Friday's after-market session. The market value of their outstanding shares is at $3.9 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved
Yahoo · Sep 23, 2026
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
SAN DIEGO, September 23, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatme
Benzinga · Sep 23, 2026
Gossamer Bio Submits NDA To FDA For Seralutinib For Treatment Of Pulmonary Arterial Hypertension
– NDA Supported by the Phase 3 PROSERA Study, Phase 2 TORREY Study and Additional Supportive Analyses –Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
